While the federal government has yet to approve Xyotax, the status means that the treatment will receive an accelerated review, likely within six months after a drug application is filed, said James Bianco, the company's chief executive.

Fast-track status is given to experimental treatments that address unmet medical needs. But analysts have pointed out that it does not increase the probability that a drug would win approval or be rejected.